TRK抑制剂治疗后转化手术治疗不可切除的腮腺分泌性癌
本文报告一例33岁男性左侧腮腺肿瘤,侵犯茎突后间隙并检出ETV6-NTRK3融合基因。给予恩曲替尼后肿瘤缩小至可手术切除并获足够切缘,行腮腺全切除加左肩胛舌骨上颈淋巴结清扫术。作者认为转化手术与TRK抑制剂对伴NTRK融合基因的不可切除腮腺癌有效,为转化手术提供参考。
要点
- 腮腺分泌性癌多可检出NTRK融合基因。
- 恩曲替尼使不可切除腮腺癌缩小至可获足够切缘切除。
- 转化手术加TRK抑制剂对伴NTRK融合基因的不可切除腮腺癌有效。
核心结论
- 转化手术与TRK抑制剂对伴NTRK融合基因的不可切除腮腺癌有效。
研究设计与样本
- 本文为病例报告,患者为33岁男性,左侧腮腺肿瘤,侵犯茎突后间隙并检出ETV6-NTRK3融合基因。
主要发现
- 恩曲替尼给药后肿瘤缩小至可手术切除并获得足够切缘。
- 患者接受腮腺全切除加左肩胛舌骨上颈淋巴结清扫术。
临床怎么用
- 作者认为转化手术与TRK抑制剂对伴NTRK融合基因的不可切除腮腺癌有效,为不可切除腮腺癌的转化手术提供参考。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The NTRK fusion gene is detected in most salivary gland secretory carcinomas. While tropomyosin receptor kinase (TRK) inhibitors are used for various solid tumors with the fusion gene, there are no reports regarding TRK inhibitor use for unresectable parotid gland carcinomas that subsequently shrink and become resectable. Here, we report a case of salivary gland secretory carcinoma in which conversion surgery was performed after TRK inhibitor use. METHODS: The patient was a 33-year-old man with a left parotid gland tumor. Examinations revealed a tumor invading the poststyloid compartment and ETV6-NTRK3 fusion gene expression. RESULTS: Entrectinib administration shrunk the tumor to a size surgically resectable with an adequate margin. The patient underwent total parotidectomy with left supraomohyoid neck dissection. CONCLUSIONS: Conversion surgery and TRK inhibitor use were effective against unresectable parotid gland carcinoma with the NTRK fusion gene. The case provides a reference for conversion surgery use for unresectable parotid gland carcinomas.
引用
- Nagano A, Matoba T, Kawakita D, et al. Conversion Surgery After Administration of a TRK Inhibitor for Unresectable Parotid Gland Secretory Carcinoma. Head Neck. 2025. PMID: 40384592. doi:10.1002/hed.28196
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。